FDA public meeting
This article was originally published in The Tan Sheet
FDA will hold a public meeting Feb. 7 to discuss potential revisions of chemistry, manufacturing and controls supplement regulations, the agency announces Jan. 5. "FDA is evaluating how it could revise its regulations to allow for consideration of risk-based approaches based on manufacturing process understanding, including prior-knowledge of similar products, and overall quality systems to provide an enhanced risk-based approach to the regulatory process, which would reduce the number of supplements," FDA writes. The agency is "considering redefining what FDA considers to be a major manufacturing change, reducing the reporting burden for certain changes, and creating a new reporting category of manufacturing changes that would not require notification to FDA." The decision is in line with FDA's Pharmaceutical Current Good Manufacturing Practices for the 21st Century Initiative (1"The Tan Sheet" July 3, 2006, p. 6). Comments should be submitted March 7...
You may also be interested in...
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.